Amneal Pharmaceuticals, Inc. $AMRX Stock Holdings Trimmed by Tucker Asset Management LLC

Tucker Asset Management LLC decreased its position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 9.0% during the fourth quarter, HoldingsChannel reports. The firm owned 1,011,064 shares of the company’s stock after selling 100,000 shares during the period. Amneal Pharmaceuticals makes up approximately 3.7% of Tucker Asset Management LLC’s holdings, making the stock its 6th biggest holding. Tucker Asset Management LLC’s holdings in Amneal Pharmaceuticals were worth $12,739,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Comerica Bank raised its position in Amneal Pharmaceuticals by 186.7% during the third quarter. Comerica Bank now owns 3,005 shares of the company’s stock valued at $30,000 after purchasing an additional 1,957 shares in the last quarter. Spire Wealth Management raised its position in Amneal Pharmaceuticals by 66.6% during the fourth quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock valued at $32,000 after purchasing an additional 1,023 shares in the last quarter. Focus Partners Wealth purchased a new stake in Amneal Pharmaceuticals during the third quarter valued at about $42,000. Advisory Services Network LLC purchased a new stake in Amneal Pharmaceuticals during the third quarter valued at about $50,000. Finally, Strs Ohio purchased a new stake in Amneal Pharmaceuticals during the fourth quarter valued at about $52,000. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Amneal Pharmaceuticals Price Performance

NASDAQ AMRX opened at $11.93 on Monday. The stock has a market capitalization of $3.81 billion, a PE ratio of 31.40 and a beta of 1.32. Amneal Pharmaceuticals, Inc. has a 1 year low of $7.02 and a 1 year high of $15.42. The business’s 50-day moving average is $12.65 and its 200 day moving average is $12.83.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its earnings results on Thursday, May 7th. The company reported $0.27 earnings per share (EPS) for the quarter. The company had revenue of $722.52 million for the quarter. Amneal Pharmaceuticals had a negative return on equity of 313.96% and a net margin of 4.01%. As a group, equities research analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.92 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on AMRX shares. Zacks Research downgraded Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 6th. Weiss Ratings upgraded Amneal Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Monday, May 11th. UBS Group started coverage on Amneal Pharmaceuticals in a research report on Friday, April 17th. They set a “buy” rating and a $19.00 price target on the stock. Finally, Truist Financial raised their price target on Amneal Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.00.

Insider Activity

In related news, Director Deborah M. Autor sold 34,819 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $12.94, for a total value of $450,557.86. Following the sale, the director directly owned 93,660 shares of the company’s stock, valued at $1,211,960.40. This trade represents a 27.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 17.30% of the stock is owned by insiders.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.